NCT05053126View on ClinicalTrials.gov

Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 27, 2021

Primary Completion Date

April 1, 2022

Study Completion Date

April 1, 2022

Conditions
Abuse Potential
Interventions
DRUG

Pregabalin 300mg

Participant will receive an oral dose of pregabalin 300 mg

DRUG

pregabalin 450 mg

Participant will receive an oral dose of pregabalin 450 mg

DRUG

Pregabalin 300 mg with oxycodone 20 mg

Participant will receive an oral dose of pregabalin 300 mg and oxycodone 20 mg

DRUG

pregabalin 450 mg with oxycodone 20 mg

Participant will receive an oral dose of pregabalin 450 mg and oxycodone 20 mg

DRUG

oxycodone 20 mg

Participant will receive an oral dose of oxycodone 20 mg

DRUG

Placebo

Participant will receive an oral dose of placebo

Trial Locations (1)

08053

Hassman Research Institute, Marlton

All Listed Sponsors
lead

Viatris Specialty LLC

INDUSTRY

NCT05053126 - Study Evaluating Abuse Potential of Lyrica® in Healthy Non-Drug Dependent Recreational Opioid Users | Biotech Hunter | Biotech Hunter